Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Betts, Gareth ^a,b   Poyntz, Hazel ^a   Stylianou, Elena ^a   Reyes Sandoval, Arturo ^a   Cottingham, Matthew ^a   Hill, Adrian ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EPITOPE; GAMMA INTERFERON; MYCOBACTERIUM ANTIGEN; VIRUS VECTOR;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; IMMUNOGENICITY; IMMUNOREACTIVITY; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS;

ACYLTRANSFERASES; ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; FEMALE; GENE EXPRESSION; GENETIC VECTORS; IMMUNIZATION, SECONDARY; INJECTIONS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; VACCINATION; VACCINIA VIRUS;

HUMAN ADENOVIRUS TYPE 5; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; VACCINIA VIRUS ANKARA;

EID: 84871349782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050447     Document Type: Article

References (34)

1. StopTBpartnership (2011) (http://www.stoptb.org/resources/factsheets/fastfacts.asp) Stop TB partnership website.Accessed 2012 Nov 25.
2. Rodrigues LC, Diwan VK, Wheeler JG, (1993) Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22: 1154-1158.
3. Kaufmann SH, (2010) Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33: 567-577.
4. McShane H, (2009) Vaccine strategies against tuberculosis. Swiss Med Wkly 139: 156-160.
5. Corbett EL, De Cock KM, (1996) Tuberculosis in the HIV-positive patient. Br J Hosp Med 56: 200-204.
6. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, et al. (1999) Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 162: 5407-5416.
7. Sousa AO, Mazzaccaro RJ, Russell RG, Lee FK, Turner OC, et al. (2000) Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Natl Acad Sci U S A 97: 4204-4208.
8. Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, et al. (2004) Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364: 2113-2121.
9. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178: 2249-2254.
10. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, et al. (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3: 148-155.
11. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
12. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, et al. (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37: 3089-3100.
13. clinicaltrials.gov (website) (http://clinicaltrials.gov/ct2/show/NCT00953927?cntry1=AF%3AZA&phase=1&rank=136) Clinical trials website.Accessed 2012 Nov 25.
14. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.
15. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, et al. (2009) MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4: e5264.
16. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, et al. (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77: 3364-3373.
17. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
18. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
19. Draper SJ, Heeney JL, (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8: 62-73.
20. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, et al. (2008) Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181: 4955-4964.
21. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z, (2006) Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74: 4634-4643.
22. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, et al. (2010) The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 181: 1407-1417.
23. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, et al. (2002) Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20: 1039-1045.
24. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, et al. (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 6: 78-83.
25. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, et al. (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78: 145-153.
26. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, et al. (2008) Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38: 732-741.
27. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV, (2002) Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 70: 1623-1626.
28. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4: 397-402.
29. Schirmbeck R, Reimann J, Kochanek S, Kreppel F, (2008) The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 16: 1609-1616.
30. Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, et al. (2006) Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80: 6318-6323.
31. Oseroff C, Kos F, Bui HH, Peters B, Pasquetto V, et al. (2005) HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A 102: 13980-13985.
32. Roederer M, Nozzi JL, Nason MX, (2011) SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A.
33. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, et al. (2007) Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 81: 6594-6604.
34. Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, et al. (2012) Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. Mol Ther Feb 21doi: 10.1038/mt.2012.25. [Epub ahead of print].